首页 > 最新文献

Ai zheng = Aizheng = Chinese journal of cancer最新文献

英文 中文
[LRP16 gene function based on bioinformatic analysis]. [LRP16基因功能的生物信息学分析]。
Pub Date : 2009-12-01 DOI: 10.5732/cjc.009.10221
Bo Yang, Xue-Chun Lu, Xiao-Hua Chi, Wei-Dong Han, Li Yu, Fang-Ding Lou

Background and objective: LRP16 is a human novel gene linked to leukemia identified recently. However, its biological function is not fully clarified so far. This study was to investigate the biological function of human LRP16 gene by database-aided bioinformatics analysis.

Methods: The structures and functions of LRP16 gene promoter and its coding protein were analyzed using bioinformatics prediction, and further experimental testing was performed. The recombinants of pGL3-basic and LRP16 promoter subclones were constructed for luciferase activity analysis. The recombinant of LRP16 open reading frame coding sequence and pcDNA3.1 eukaryotic expression vector was established and transfected into HL-60 and K562 cell lines. DNA damage of HL-60 cells after ultraviolet irradiation was evaluated using single cell gel electrophoresis. Cell cycle of K562 cells was analyzed by flow cytometry.

Results: LRP16 promoter was a typical class II eukaryotic promoter and its core regulation sequence was located within upstream -600 bp of transcriptional start site. In addition, seven cis-acting elements, which may be implicated in cell cycle, hematopoiesis regulation, cell proliferation and repair of DNA damage, were identified. Long type LRP16 coding protein contained homologous sequences of hismacro, COG2110, and A1pp with human histone H2A1C between 148 and 315 amino acid residue. The number of comet cells and the length of comet tail in HL-60 cells irradiated were significantly decreased and the number of living cell was significantly increased in LRP16-overexpression group compared with empty plasmid control group. The proliferation rate and ratio or quantity of G2/M and S phases were significantly increased in LRP16-overexpression K562 group compared with empty plasmid control group. LRP16-overexpression in K562 cells promoted the transition of G1 to S phase and plateau phase of cell proliferation was advanced.

Conclusions: Promoter regulation prediction and protein domain analysis based on bioinformatics contribute to the study of gene function. LRP16 may play an important role in leukemia progression by promoting cell proliferation, regulating cell cycle, and antagonizing radiation-induced DNA damage.

背景与目的:LRP16是最近发现的与白血病相关的人类新基因。然而,其生物学功能至今尚未完全阐明。本研究旨在通过数据库辅助生物信息学分析,探讨人LRP16基因的生物学功能。方法:采用生物信息学预测方法分析LRP16基因启动子及其编码蛋白的结构和功能,并进行进一步的实验检验。构建pGL3-basic和LRP16启动子亚克隆重组体进行荧光素酶活性分析。构建重组LRP16开放阅读框编码序列和pcDNA3.1真核表达载体,分别转染HL-60和K562细胞系。采用单细胞凝胶电泳法观察紫外线照射后HL-60细胞的DNA损伤情况。流式细胞术分析K562细胞的细胞周期。结果:LRP16启动子是典型的II类真核启动子,其核心调控序列位于转录起始位点上游- 600bp。此外,还发现了7个可能参与细胞周期、造血调节、细胞增殖和DNA损伤修复的顺式作用元件。长型LRP16编码蛋白含有与人组蛋白H2A1C同源的hismacro、COG2110和A1pp序列,残基在148 ~ 315个氨基酸之间。与空质粒对照组相比,lrp16过表达组辐照后HL-60细胞中彗星细胞数量和彗尾长度显著减少,活细胞数量显著增加。与空质粒对照组相比,过表达lrp16的K562组细胞增殖率、G2/M期和S期的比例或数量均显著增加。lrp16在K562细胞中的过表达促进细胞G1期向S期过渡,细胞增殖平台期提前。结论:基于生物信息学的启动子调控预测和蛋白结构域分析有助于基因功能的研究。LRP16可能通过促进细胞增殖、调节细胞周期和拮抗辐射诱导的DNA损伤在白血病进展中发挥重要作用。
{"title":"[LRP16 gene function based on bioinformatic analysis].","authors":"Bo Yang,&nbsp;Xue-Chun Lu,&nbsp;Xiao-Hua Chi,&nbsp;Wei-Dong Han,&nbsp;Li Yu,&nbsp;Fang-Ding Lou","doi":"10.5732/cjc.009.10221","DOIUrl":"https://doi.org/10.5732/cjc.009.10221","url":null,"abstract":"<p><strong>Background and objective: </strong>LRP16 is a human novel gene linked to leukemia identified recently. However, its biological function is not fully clarified so far. This study was to investigate the biological function of human LRP16 gene by database-aided bioinformatics analysis.</p><p><strong>Methods: </strong>The structures and functions of LRP16 gene promoter and its coding protein were analyzed using bioinformatics prediction, and further experimental testing was performed. The recombinants of pGL3-basic and LRP16 promoter subclones were constructed for luciferase activity analysis. The recombinant of LRP16 open reading frame coding sequence and pcDNA3.1 eukaryotic expression vector was established and transfected into HL-60 and K562 cell lines. DNA damage of HL-60 cells after ultraviolet irradiation was evaluated using single cell gel electrophoresis. Cell cycle of K562 cells was analyzed by flow cytometry.</p><p><strong>Results: </strong>LRP16 promoter was a typical class II eukaryotic promoter and its core regulation sequence was located within upstream -600 bp of transcriptional start site. In addition, seven cis-acting elements, which may be implicated in cell cycle, hematopoiesis regulation, cell proliferation and repair of DNA damage, were identified. Long type LRP16 coding protein contained homologous sequences of hismacro, COG2110, and A1pp with human histone H2A1C between 148 and 315 amino acid residue. The number of comet cells and the length of comet tail in HL-60 cells irradiated were significantly decreased and the number of living cell was significantly increased in LRP16-overexpression group compared with empty plasmid control group. The proliferation rate and ratio or quantity of G2/M and S phases were significantly increased in LRP16-overexpression K562 group compared with empty plasmid control group. LRP16-overexpression in K562 cells promoted the transition of G1 to S phase and plateau phase of cell proliferation was advanced.</p><p><strong>Conclusions: </strong>Promoter regulation prediction and protein domain analysis based on bioinformatics contribute to the study of gene function. LRP16 may play an important role in leukemia progression by promoting cell proliferation, regulating cell cycle, and antagonizing radiation-induced DNA damage.</p>","PeriodicalId":7559,"journal":{"name":"Ai zheng = Aizheng = Chinese journal of cancer","volume":"28 12","pages":"1283-90"},"PeriodicalIF":0.0,"publicationDate":"2009-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28547205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
[Progress on the subcellular localization of Daxx]. [Daxx亚细胞定位研究进展]。
Pub Date : 2009-12-01 DOI: 10.5732/cjc.009.10168
Su-Fang Chen, Cui-Ming Zhu, Yan-Ping Wan

As a highly conserved nuclear protein, death domain-associated protein(Daxx) plays an important role in transcriptional control, carcinogenesis, resistance to virus infection, and so on. Daxx can be localized in promyleocytic leukaemia protein oncogenic domains, nucleoplasm, nucleolus, cytoplasm, and heterochromatin. The subcellular localization of Daxx can be changed by modification or interacting with other proteins. Under cellular stress, Daxx can interact with many kinds of molecules, and thus affect its downstream signaling pathway. The purpose of this review was to discuss Daxx's subcellular localization in different conditions and its translocation between subcellular compartments.

死亡结构域相关蛋白(death domain-associated protein, Daxx)是一种高度保守的核蛋白,在转录调控、致癌、抵抗病毒感染等方面发挥着重要作用。Daxx可定位于早幼粒细胞白血病蛋白致癌区域、核质、核核、细胞质和异染色质。Daxx的亚细胞定位可以通过修饰或与其他蛋白相互作用而改变。在细胞应激下,Daxx可以与多种分子相互作用,从而影响其下游信号通路。本综述的目的是讨论Daxx在不同条件下的亚细胞定位及其在亚细胞区室之间的易位。
{"title":"[Progress on the subcellular localization of Daxx].","authors":"Su-Fang Chen,&nbsp;Cui-Ming Zhu,&nbsp;Yan-Ping Wan","doi":"10.5732/cjc.009.10168","DOIUrl":"https://doi.org/10.5732/cjc.009.10168","url":null,"abstract":"<p><p>As a highly conserved nuclear protein, death domain-associated protein(Daxx) plays an important role in transcriptional control, carcinogenesis, resistance to virus infection, and so on. Daxx can be localized in promyleocytic leukaemia protein oncogenic domains, nucleoplasm, nucleolus, cytoplasm, and heterochromatin. The subcellular localization of Daxx can be changed by modification or interacting with other proteins. Under cellular stress, Daxx can interact with many kinds of molecules, and thus affect its downstream signaling pathway. The purpose of this review was to discuss Daxx's subcellular localization in different conditions and its translocation between subcellular compartments.</p>","PeriodicalId":7559,"journal":{"name":"Ai zheng = Aizheng = Chinese journal of cancer","volume":"28 12","pages":"1333-6"},"PeriodicalIF":0.0,"publicationDate":"2009-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28546010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
[Clinical characteristics and prognosis of very young patients with breast cancer in the southern of China]. 【中国南方地区极年轻乳腺癌患者的临床特点及预后分析】。
Pub Date : 2009-12-01 DOI: 10.5732/cjc.009.10230
Hua Yang, Si-Yu Wang, Wei Ou, Hai-Bo Sun, Qin Fang

Background and objective: Even though most breast cancers occur in postmenopausal women in western countries, age <35 is one of the prognostic factors. This study was to compare the clinicopathologic characteristics and prognosis between premenopausal breast cancer patients aged of <35 and > or =35 in south China, and to explore the prognostic factors.

Methods: A total of 905 consecutive premenopausal patients were evaluated, with first diagnosis of breast cancer referred to surgery at the Sun Yat-sen University Cancer Center from October 2003 to December 2006. The clinicopathologic factors and the survival rates between the very young group(aged of <35 at diagnosis) and the non-young group(aged of > or =35 at diagnosis) were retrospectively compared.

Results: The overall median follow-up time was 27.77 months. The 3-year disease-free survival rate was significantly lower (78.0% vs. 89.1%, P<0.001) and the 3-year survival rate relatively lower(94.3% vs. 96.8%, P=0.10) in the very young group than in the non-young group. In addition, the 3-year survival and disease-free survival rates were significantly lower in the very young group with HR (hormone receptor)-positive than in the non-young group (P<0.05). The univariate and multivariate analysis of clinicopathologic characteristics between two groups showed that age <35 at diagnosis, axillary lymph node involvement, presence of vascular invasion, and high expression of Ki67 were risk factors for recurrence.

Conclusion: Compared with non-young premenopausal patients, very young breast patients with HR-positive cancer have a worse outcome.

背景与目的:尽管西方国家大多数乳腺癌发生在绝经后妇女,但在中国南方,年龄≥35岁的妇女发生乳腺癌,并探讨其预后因素。方法:对2003年10月至2006年12月中山大学肿瘤中心首次诊断为乳腺癌并行手术治疗的905例连续绝经前患者进行评估。回顾性比较非常年轻组(诊断时年龄≤35岁)的临床病理因素和生存率。结果:总中位随访时间为27.77个月。结论:与非年轻绝经前患者相比,非常年轻的hr阳性乳腺癌患者预后较差。
{"title":"[Clinical characteristics and prognosis of very young patients with breast cancer in the southern of China].","authors":"Hua Yang,&nbsp;Si-Yu Wang,&nbsp;Wei Ou,&nbsp;Hai-Bo Sun,&nbsp;Qin Fang","doi":"10.5732/cjc.009.10230","DOIUrl":"https://doi.org/10.5732/cjc.009.10230","url":null,"abstract":"<p><strong>Background and objective: </strong>Even though most breast cancers occur in postmenopausal women in western countries, age <35 is one of the prognostic factors. This study was to compare the clinicopathologic characteristics and prognosis between premenopausal breast cancer patients aged of <35 and > or =35 in south China, and to explore the prognostic factors.</p><p><strong>Methods: </strong>A total of 905 consecutive premenopausal patients were evaluated, with first diagnosis of breast cancer referred to surgery at the Sun Yat-sen University Cancer Center from October 2003 to December 2006. The clinicopathologic factors and the survival rates between the very young group(aged of <35 at diagnosis) and the non-young group(aged of > or =35 at diagnosis) were retrospectively compared.</p><p><strong>Results: </strong>The overall median follow-up time was 27.77 months. The 3-year disease-free survival rate was significantly lower (78.0% vs. 89.1%, P<0.001) and the 3-year survival rate relatively lower(94.3% vs. 96.8%, P=0.10) in the very young group than in the non-young group. In addition, the 3-year survival and disease-free survival rates were significantly lower in the very young group with HR (hormone receptor)-positive than in the non-young group (P<0.05). The univariate and multivariate analysis of clinicopathologic characteristics between two groups showed that age <35 at diagnosis, axillary lymph node involvement, presence of vascular invasion, and high expression of Ki67 were risk factors for recurrence.</p><p><strong>Conclusion: </strong>Compared with non-young premenopausal patients, very young breast patients with HR-positive cancer have a worse outcome.</p>","PeriodicalId":7559,"journal":{"name":"Ai zheng = Aizheng = Chinese journal of cancer","volume":"28 12","pages":"1310-6"},"PeriodicalIF":0.0,"publicationDate":"2009-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28546006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
[Germ-line epimutations and human cancer]. [种系增殖与人类癌症]。
Pub Date : 2009-12-01 DOI: 10.5732/cjc.009.10266
Pu-Yuan Wu, Yi-Mei Fan, Ya-Ping Wang

Epimutations are errors in the normal process of epigenetic regulation which can result in aberrant transcriptional silencing of a normally active gene or reactivation of a normally silent gene. Epimutations are generally considered to be somatic events and to be confined in affected tissues. However, recent studies of patients with hereditary nonpolyposis colorectal cancer (HNPCC) have showed that allele-specific hypermethylation of CpG islands in the promoter region of the MLH1 gene, one of the causes of the tumor, existed in all the tissues examined. In addition, germ-line epimutations of other tumor suppressor genes (TSGs), such as MSH2 and BRCA1, have also been reported, demonstrating that epimutations might arise in the germ-line (during gametogenesis or early embryonic development). The role of germ-line epimutations might be as important as germ-line mutations in human disease. We reviewed the update on germ-line epimutations of TSGs including the possible mechanisms underlying germ-line epimutations, the possibility of transgenerational inheritance, and their impact on our understanding of human disease.

表观突变是正常表观遗传调控过程中的错误,可导致正常活性基因的异常转录沉默或正常沉默基因的再激活。上皮化通常被认为是躯体事件,局限于受影响的组织。然而,最近对遗传性非息肉病性结直肠癌(HNPCC)患者的研究表明,MLH1基因启动子区CpG岛的等位基因特异性高甲基化是肿瘤的原因之一,在所有检查的组织中都存在。此外,其他肿瘤抑制基因(TSGs),如MSH2和BRCA1的种系表位突变也有报道,表明表位突变可能发生在种系(配子体发生或早期胚胎发育期间)。在人类疾病中,种系突变的作用可能与种系突变一样重要。我们回顾了tsg的生殖系变异的最新进展,包括生殖系变异的可能机制、跨代遗传的可能性以及它们对我们对人类疾病的理解的影响。
{"title":"[Germ-line epimutations and human cancer].","authors":"Pu-Yuan Wu,&nbsp;Yi-Mei Fan,&nbsp;Ya-Ping Wang","doi":"10.5732/cjc.009.10266","DOIUrl":"https://doi.org/10.5732/cjc.009.10266","url":null,"abstract":"<p><p>Epimutations are errors in the normal process of epigenetic regulation which can result in aberrant transcriptional silencing of a normally active gene or reactivation of a normally silent gene. Epimutations are generally considered to be somatic events and to be confined in affected tissues. However, recent studies of patients with hereditary nonpolyposis colorectal cancer (HNPCC) have showed that allele-specific hypermethylation of CpG islands in the promoter region of the MLH1 gene, one of the causes of the tumor, existed in all the tissues examined. In addition, germ-line epimutations of other tumor suppressor genes (TSGs), such as MSH2 and BRCA1, have also been reported, demonstrating that epimutations might arise in the germ-line (during gametogenesis or early embryonic development). The role of germ-line epimutations might be as important as germ-line mutations in human disease. We reviewed the update on germ-line epimutations of TSGs including the possible mechanisms underlying germ-line epimutations, the possibility of transgenerational inheritance, and their impact on our understanding of human disease.</p>","PeriodicalId":7559,"journal":{"name":"Ai zheng = Aizheng = Chinese journal of cancer","volume":"28 12","pages":"1236-42"},"PeriodicalIF":0.0,"publicationDate":"2009-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28546164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
[Correlation of the sensitivity of NP chemotherapy in non-small lung cancer with DNA repair gene XRCC1 polymorphism]. [非小细胞肺癌NP化疗敏感性与DNA修复基因XRCC1多态性的相关性]。
Pub Date : 2009-12-01 DOI: 10.5732/cjc.009.10139
Cheng-Yu Hong, Qian Xu, Zheng Yue, Ye Zhang, Yuan Yuan

Background and objective: The gene polymorphism is used to predict the sensitivity of chemotherapy, which is significant for the individualized treatment of tumor. This study was to explore the correlation of codon 194 and codon 399 polymorphisms of DNA repair gene X-ray repair cross complementing (XRCC1) with the sensitivity of non-small cell lung cancer (NSCLC) to NP (vinorebine and cisplatin) chemotherapy.

Methods: XRCC1 polymorphisms at codon 194 and codon 399 were detected in 164 patients with NSCLC using polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP). The haplotype of XRCC1 gene was analyzed using SHEsis analysis software. Patients treated with NP chemotherapy were evaluated after two periods of treatment, then the correlation of the sensitivity of chemotherapy with polymorphisms was analyzed.

Results: The patients with the XRCC1 codon 194 C/T+T/T polymorphisms were 2.038 times as sensitive to the chemotherapy as the patients with C/C genotype (P=0.036, 95% CI:1.044-3.976). The effective rate to chemotherapy was no significant difference between the patients with XRCC1 codon 399 G/G, A/G, and A/A polymorhism. The effective rate of chemotherapy of the patients with T-A haplotype significantly increased compared with those with other haplotype (P=0.031), while that of the patients with C-A haplotype significantly decreased compared with others(P=0.035).

Conclusions: The sensitivity to NP chemotherapy significantly increased in the NSCLC patients with XRCC1 194 CT and TT genotypes compared with those with CC genotype. XRCC1 codon 194 and codon 399 polymorphisms may be used to predict the sensitivity of NSCLC to NP chemotherapy.

背景与目的:利用基因多态性预测化疗敏感性,对肿瘤的个体化治疗具有重要意义。本研究旨在探讨DNA修复基因x射线修复交叉互补(XRCC1)密码子194和399多态性与非小细胞肺癌(NSCLC)对NP(长春瑞滨和顺铂)化疗敏感性的关系。方法:采用聚合酶链反应限制性片段长度多态性(PCR-RFLP)检测164例非小细胞肺癌患者中XRCC1密码子194和399位点的多态性。采用SHEsis分析软件分析XRCC1基因的单倍型。两期治疗后对NP化疗患者进行评价,分析化疗敏感性与基因多态性的相关性。结果:XRCC1密码子194 C/T+T/T多态性患者对化疗的敏感性是C/C基因型患者的2.038倍(P=0.036, 95% CI:1.044 ~ 3.976)。XRCC1密码子399 G/G、A/G、A/A多态性患者的化疗有效率无显著差异。T-A单倍型患者化疗有效率显著高于其他单倍型患者(P=0.031), C-A单倍型患者化疗有效率显著低于其他单倍型患者(P=0.035)。结论:XRCC1 194 CT和TT基因型NSCLC患者对NP化疗的敏感性明显高于CC基因型患者。XRCC1密码子194和密码子399多态性可用于预测NSCLC对NP化疗的敏感性。
{"title":"[Correlation of the sensitivity of NP chemotherapy in non-small lung cancer with DNA repair gene XRCC1 polymorphism].","authors":"Cheng-Yu Hong,&nbsp;Qian Xu,&nbsp;Zheng Yue,&nbsp;Ye Zhang,&nbsp;Yuan Yuan","doi":"10.5732/cjc.009.10139","DOIUrl":"https://doi.org/10.5732/cjc.009.10139","url":null,"abstract":"<p><strong>Background and objective: </strong>The gene polymorphism is used to predict the sensitivity of chemotherapy, which is significant for the individualized treatment of tumor. This study was to explore the correlation of codon 194 and codon 399 polymorphisms of DNA repair gene X-ray repair cross complementing (XRCC1) with the sensitivity of non-small cell lung cancer (NSCLC) to NP (vinorebine and cisplatin) chemotherapy.</p><p><strong>Methods: </strong>XRCC1 polymorphisms at codon 194 and codon 399 were detected in 164 patients with NSCLC using polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP). The haplotype of XRCC1 gene was analyzed using SHEsis analysis software. Patients treated with NP chemotherapy were evaluated after two periods of treatment, then the correlation of the sensitivity of chemotherapy with polymorphisms was analyzed.</p><p><strong>Results: </strong>The patients with the XRCC1 codon 194 C/T+T/T polymorphisms were 2.038 times as sensitive to the chemotherapy as the patients with C/C genotype (P=0.036, 95% CI:1.044-3.976). The effective rate to chemotherapy was no significant difference between the patients with XRCC1 codon 399 G/G, A/G, and A/A polymorhism. The effective rate of chemotherapy of the patients with T-A haplotype significantly increased compared with those with other haplotype (P=0.031), while that of the patients with C-A haplotype significantly decreased compared with others(P=0.035).</p><p><strong>Conclusions: </strong>The sensitivity to NP chemotherapy significantly increased in the NSCLC patients with XRCC1 194 CT and TT genotypes compared with those with CC genotype. XRCC1 codon 194 and codon 399 polymorphisms may be used to predict the sensitivity of NSCLC to NP chemotherapy.</p>","PeriodicalId":7559,"journal":{"name":"Ai zheng = Aizheng = Chinese journal of cancer","volume":"28 12","pages":"1291-7"},"PeriodicalIF":0.0,"publicationDate":"2009-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28546003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 20
EBV conference establishes goals for defining disease-related EBV subtypes for vaccine development. EBV 会议确定了为疫苗开发定义疾病相关 EBV 亚型的目标。
Laurie Goodman
{"title":"EBV conference establishes goals for defining disease-related EBV subtypes for vaccine development.","authors":"Laurie Goodman","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":7559,"journal":{"name":"Ai zheng = Aizheng = Chinese journal of cancer","volume":"28 12","pages":"1233-5"},"PeriodicalIF":0.0,"publicationDate":"2009-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28546162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Efficacy and survival of 92 cases of Ewing's sarcoma family of tumor initially treated with multidisciplinary therapy]. [92例Ewing肉瘤家族肿瘤首发多学科治疗的疗效及生存率分析]。
Pub Date : 2009-12-01 DOI: 10.5732/cjc.008.10609
Rou-Jun Peng, Xiao-Fei Sun, Xiao-Juan Xiang, Zi-Jun Zhen, Jia-Yu Ling, Gang-Ling Tong, Yi Xia, Guang-Chuang Xu, Wen-Qi Jiang

Background and objective: Ewing's sarcoma family of tumor (ESFT) is aggressive. The optimal therapy modality for ESFT is still to be found. This study was to explore the clinical characteristics and therapy for ESFT.

Methods: Ninety-two cases of ESFT were collected from January 1995 to April 2008 in Sun Yat-sen University Cancer Center and analyzed retrospectively.

Result: Of 92 cases, 23 were Ewing's sarcoma of bone, 21 extraosseous Ewing's sarcoma, 43 peripheral primitive neuroectodermal tumor, and 5 Askin tumor. Median follow-up time was 31.5 months (range, 10-137 months). Thirty-eight patients received multidisciplinary therapy and 19 single model therapy in non-metastasis group. Three-year overall survival (OS) and event-free survival (EFS) were significantly different between non-metastatic multidisciplinary therapy group and non-metastatic single model group (63% vs. 20%, 46% vs. 18%, respectively, P<0.001). The patients who received surgery plus chemotherapy and plus radiation or not had longer survival than those treated with chemotherapy plus radiation in non-metastatic multidisciplinary therapy group (Chi2=7.591, 9.212; P=0.006, 0.002). CAV/IE alternative regimen was superior to other regimens in event-free survival, but not in overall survival (Chi2=6.950, 3.530; P=0.008, 0.06). Cox regression analysis suggested therapy model and response to treatment were independent prognostic factors for ESFT.

Conclusions: Our studying showed multidisciplinary therapy could significantly improve non-metastatic ESFT patients' survival. Chemotherapy plus surgery and plus radiation or not were superior to chemotherapy plus radiation in local control for the non-metastatic ESFT. Therapy model and response were independent prognostic factors.

背景与目的:尤文氏肉瘤家族肿瘤(Ewing’s sarcoma family of tumor, ESFT)具有侵袭性。ESFT的最佳治疗方式仍有待发现。本研究旨在探讨ESFT的临床特点及治疗方法。方法:对1995年1月~ 2008年4月中山大学肿瘤中心收治的92例ESFT患者进行回顾性分析。结果:92例患者中,骨内尤文氏肉瘤23例,骨外尤文氏肉瘤21例,外周原始神经外胚层肿瘤43例,Askin肿瘤5例。中位随访时间为31.5个月(范围10-137个月)。非转移组多学科治疗38例,单模式治疗19例。3年总生存率(OS)和无事件生存率(EFS)在非转移性多学科治疗组和非转移性单模型组之间差异显著(分别为63% vs. 20%, 46% vs. 18%)。结论:本研究显示多学科治疗可显著提高非转移性ESFT患者的生存率。在非转移性ESFT的局部对照中,化疗加手术、加放疗或不加放疗优于化疗加放疗。治疗模式和疗效是独立的预后因素。
{"title":"[Efficacy and survival of 92 cases of Ewing's sarcoma family of tumor initially treated with multidisciplinary therapy].","authors":"Rou-Jun Peng,&nbsp;Xiao-Fei Sun,&nbsp;Xiao-Juan Xiang,&nbsp;Zi-Jun Zhen,&nbsp;Jia-Yu Ling,&nbsp;Gang-Ling Tong,&nbsp;Yi Xia,&nbsp;Guang-Chuang Xu,&nbsp;Wen-Qi Jiang","doi":"10.5732/cjc.008.10609","DOIUrl":"https://doi.org/10.5732/cjc.008.10609","url":null,"abstract":"<p><strong>Background and objective: </strong>Ewing's sarcoma family of tumor (ESFT) is aggressive. The optimal therapy modality for ESFT is still to be found. This study was to explore the clinical characteristics and therapy for ESFT.</p><p><strong>Methods: </strong>Ninety-two cases of ESFT were collected from January 1995 to April 2008 in Sun Yat-sen University Cancer Center and analyzed retrospectively.</p><p><strong>Result: </strong>Of 92 cases, 23 were Ewing's sarcoma of bone, 21 extraosseous Ewing's sarcoma, 43 peripheral primitive neuroectodermal tumor, and 5 Askin tumor. Median follow-up time was 31.5 months (range, 10-137 months). Thirty-eight patients received multidisciplinary therapy and 19 single model therapy in non-metastasis group. Three-year overall survival (OS) and event-free survival (EFS) were significantly different between non-metastatic multidisciplinary therapy group and non-metastatic single model group (63% vs. 20%, 46% vs. 18%, respectively, P<0.001). The patients who received surgery plus chemotherapy and plus radiation or not had longer survival than those treated with chemotherapy plus radiation in non-metastatic multidisciplinary therapy group (Chi2=7.591, 9.212; P=0.006, 0.002). CAV/IE alternative regimen was superior to other regimens in event-free survival, but not in overall survival (Chi2=6.950, 3.530; P=0.008, 0.06). Cox regression analysis suggested therapy model and response to treatment were independent prognostic factors for ESFT.</p><p><strong>Conclusions: </strong>Our studying showed multidisciplinary therapy could significantly improve non-metastatic ESFT patients' survival. Chemotherapy plus surgery and plus radiation or not were superior to chemotherapy plus radiation in local control for the non-metastatic ESFT. Therapy model and response were independent prognostic factors.</p>","PeriodicalId":7559,"journal":{"name":"Ai zheng = Aizheng = Chinese journal of cancer","volume":"28 12","pages":"1304-9"},"PeriodicalIF":0.0,"publicationDate":"2009-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28546005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
[Efficacy of surgical resection of left and right transthoracic approaches for middle thoracic esophageal squamous cell carcinoma]. [左、右经胸入路手术切除治疗中胸食管鳞状细胞癌的疗效]。
Pub Date : 2009-12-01 DOI: 10.5732/cjc.008.10660
Kong-Jia Luo, Jian-Hua Fu, Yi Hu, Tie-Hua Rong, Peng Lin, Xin Wang, Hong Yang, Bin Zheng, Yong-Feng Li

Background and objective: For squamous cell carcinoma of the middle thoracic esophagus, surgical resection of left or right transthoracic approach has its advantages and disadvantages, respectively. This study was to compare the outcomes between the two approaches.

Methods: A total of 482 consecutive patients with middle thoracic esophageal squamous cell carcinoma (ESCC) underwent transthoracic esophagectomy between January 1999 and June 2005. These patients were divided into left transthoracic approach group (n=350) and right transthoracic approach group (n=132). Surgical resection rate, postoperative complications, lymphadenectomy, recurrence pattern, disease-free survival, and overall survival of the two groups were compared retrospectively.

Results: The surgical resection rate was 92.0% in left approach group and 92.4% in right approach group (P=0.878). The incidence of postoperative complications was higher in right approach group than in left approach group (57.6% vs. 35.4%, P<0.001). The average number of lymph nodes resected was 11.8+/-6.6 in left approach group and 16.3+/-8.0 in right approach group (P<0.001). Lymphatic recurrence rate was lower in right approach group than in left approach group (51.1% vs. 69.6%,P=0.028), especially occurring to mediastinal lymph nodes (15.6% vs. 38.4%,P=0.005). Three-year disease-free survival was higher in right approach group than in left approach group(22.92+/-0.74 vs. 25.09+/-1.22, P=0.039).

Conclusion: Although left transthoracic resection reduced the incidence of postoperative complications, esophagectomy of right transthoracic approach was more effective in survival improvement.

背景与目的:对于胸中段食管鳞状细胞癌,经胸左入路或经胸右入路手术切除各有优缺点。本研究旨在比较两种方法的结果。方法:1999年1月至2005年6月,共482例连续的胸椎中段食管鳞状细胞癌(ESCC)患者行经胸食管切除术。分为左经胸入路组(n=350)和右经胸入路组(n=132)。回顾性比较两组患者的手术切除率、术后并发症、淋巴结切除术、复发方式、无病生存期及总生存期。结果:左入路组手术切除率为92.0%,右入路组为92.4% (P=0.878)。右入路组术后并发症发生率高于左入路组(57.6% vs. 35.4%)。结论:虽然经胸左入路可降低术后并发症发生率,但经胸右入路食管切除术在改善生存方面更有效。
{"title":"[Efficacy of surgical resection of left and right transthoracic approaches for middle thoracic esophageal squamous cell carcinoma].","authors":"Kong-Jia Luo,&nbsp;Jian-Hua Fu,&nbsp;Yi Hu,&nbsp;Tie-Hua Rong,&nbsp;Peng Lin,&nbsp;Xin Wang,&nbsp;Hong Yang,&nbsp;Bin Zheng,&nbsp;Yong-Feng Li","doi":"10.5732/cjc.008.10660","DOIUrl":"https://doi.org/10.5732/cjc.008.10660","url":null,"abstract":"<p><strong>Background and objective: </strong>For squamous cell carcinoma of the middle thoracic esophagus, surgical resection of left or right transthoracic approach has its advantages and disadvantages, respectively. This study was to compare the outcomes between the two approaches.</p><p><strong>Methods: </strong>A total of 482 consecutive patients with middle thoracic esophageal squamous cell carcinoma (ESCC) underwent transthoracic esophagectomy between January 1999 and June 2005. These patients were divided into left transthoracic approach group (n=350) and right transthoracic approach group (n=132). Surgical resection rate, postoperative complications, lymphadenectomy, recurrence pattern, disease-free survival, and overall survival of the two groups were compared retrospectively.</p><p><strong>Results: </strong>The surgical resection rate was 92.0% in left approach group and 92.4% in right approach group (P=0.878). The incidence of postoperative complications was higher in right approach group than in left approach group (57.6% vs. 35.4%, P<0.001). The average number of lymph nodes resected was 11.8+/-6.6 in left approach group and 16.3+/-8.0 in right approach group (P<0.001). Lymphatic recurrence rate was lower in right approach group than in left approach group (51.1% vs. 69.6%,P=0.028), especially occurring to mediastinal lymph nodes (15.6% vs. 38.4%,P=0.005). Three-year disease-free survival was higher in right approach group than in left approach group(22.92+/-0.74 vs. 25.09+/-1.22, P=0.039).</p><p><strong>Conclusion: </strong>Although left transthoracic resection reduced the incidence of postoperative complications, esophagectomy of right transthoracic approach was more effective in survival improvement.</p>","PeriodicalId":7559,"journal":{"name":"Ai zheng = Aizheng = Chinese journal of cancer","volume":"28 12","pages":"1260-4"},"PeriodicalIF":0.0,"publicationDate":"2009-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28547201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
[Expression of TEIF protein in colorectal tumors and its correlation with centrosome abnormality]. [TEIF蛋白在结直肠肿瘤中的表达及其与中心体异常的关系]。
Pub Date : 2009-12-01 DOI: 10.5732/cjc.009.10162
Ying Gao, Bo Zhang

Background and objective: Telomerase transcriptional elements-interacting factor (TEIF) gene found recently by our research group is a transcription factor of a kind of human telomerase reverse transcriptase (hTERT) gene, and expresses in many kinds of tumor tissues. This study was to evaluate the expression of TEIF protein in human colorectal tumors and to explore its correlation with centrosome abnormality.

Methods: The expression of TEIF in 10 specimens of normal intestinal mucosa tissue, 30 specimens of colorectal cancer, and 54 specimens of colorectal adenoma was detected by immunohistochemistry. The expression of gamma-tubulin was detected by immunofluorescence.

Results: Immunohistochemistry results showed that the differences of TEIF protein expression between the normal group and each tumor groups were statistically significant (P<0.01), and the difference of TEIF protein expression between the malignant tumor group and the benign group was not significant (P>0.05). TEIF strong positive rate (> or =++) was significantly higher in the carcinoma group than in the adenoma group or normal group (all P<0.001); the differences of TEIF strong positive rate between Grade I adenoma and Grade II or III adenoma were statistically significant (P<0.05), and the difference of TEIF strong positive rate between Grade II adenoma and Grade III adenoma was not statistically significant (P>0.05). Immunofluorescence results showed that centrosome amplification-positive rate was significantly higher in the colorectal cancer group than in the normal group or the adenoma group (both P<0.01); the difference of the centrosome amplification positive rate between Grade I adenoma and Grade III adenoma was statistically significant (P<0.05), and the differences of the centrosome amplification positive rate between Grade II adenoma and Grade I or III adenoma were statistically significant (P>0.05).

Conclusions: TEIF protein and centrosome amplification is commonly found in colorectal tumors. The expression level of TEIF is related to tumor histological grade and malignant degree. TEIF protein expression and centrosome amplification showed a high degree of positive correlation.

背景与目的:本课题组最近发现的端粒酶转录元件相互作用因子(TEIF)基因是一类人端粒酶逆转录酶(hTERT)基因的转录因子,在多种肿瘤组织中表达。本研究旨在评价TEIF蛋白在人类结直肠肿瘤中的表达,并探讨其与中心体异常的关系。方法:采用免疫组化方法检测10例正常肠黏膜组织、30例结直肠癌和54例结直肠腺瘤组织中TEIF的表达。免疫荧光法检测γ -微管蛋白的表达。结果:免疫组化结果显示,正常组与各肿瘤组TEIF蛋白表达差异均有统计学意义(P0.05)。TEIF强阳性率(>或=++)在癌组明显高于腺瘤组和正常组(均P0.05)。免疫荧光结果显示,结直肠癌组中心体扩增阳性率明显高于正常组和腺瘤组(P0.05)。结论:TEIF蛋白及中心体扩增在结直肠肿瘤中普遍存在。TEIF的表达水平与肿瘤组织学分级及恶性程度有关。TEIF蛋白表达与中心体扩增呈高度正相关。
{"title":"[Expression of TEIF protein in colorectal tumors and its correlation with centrosome abnormality].","authors":"Ying Gao,&nbsp;Bo Zhang","doi":"10.5732/cjc.009.10162","DOIUrl":"https://doi.org/10.5732/cjc.009.10162","url":null,"abstract":"<p><strong>Background and objective: </strong>Telomerase transcriptional elements-interacting factor (TEIF) gene found recently by our research group is a transcription factor of a kind of human telomerase reverse transcriptase (hTERT) gene, and expresses in many kinds of tumor tissues. This study was to evaluate the expression of TEIF protein in human colorectal tumors and to explore its correlation with centrosome abnormality.</p><p><strong>Methods: </strong>The expression of TEIF in 10 specimens of normal intestinal mucosa tissue, 30 specimens of colorectal cancer, and 54 specimens of colorectal adenoma was detected by immunohistochemistry. The expression of gamma-tubulin was detected by immunofluorescence.</p><p><strong>Results: </strong>Immunohistochemistry results showed that the differences of TEIF protein expression between the normal group and each tumor groups were statistically significant (P<0.01), and the difference of TEIF protein expression between the malignant tumor group and the benign group was not significant (P>0.05). TEIF strong positive rate (> or =++) was significantly higher in the carcinoma group than in the adenoma group or normal group (all P<0.001); the differences of TEIF strong positive rate between Grade I adenoma and Grade II or III adenoma were statistically significant (P<0.05), and the difference of TEIF strong positive rate between Grade II adenoma and Grade III adenoma was not statistically significant (P>0.05). Immunofluorescence results showed that centrosome amplification-positive rate was significantly higher in the colorectal cancer group than in the normal group or the adenoma group (both P<0.01); the difference of the centrosome amplification positive rate between Grade I adenoma and Grade III adenoma was statistically significant (P<0.05), and the differences of the centrosome amplification positive rate between Grade II adenoma and Grade I or III adenoma were statistically significant (P>0.05).</p><p><strong>Conclusions: </strong>TEIF protein and centrosome amplification is commonly found in colorectal tumors. The expression level of TEIF is related to tumor histological grade and malignant degree. TEIF protein expression and centrosome amplification showed a high degree of positive correlation.</p>","PeriodicalId":7559,"journal":{"name":"Ai zheng = Aizheng = Chinese journal of cancer","volume":"28 12","pages":"1277-82"},"PeriodicalIF":0.0,"publicationDate":"2009-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28547204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
[Metastatic alveolar soft tissue sarcoma of the central nervous system: a clinicopathological analysis of four cases]. 【中枢神经系统转移性肺泡软组织肉瘤:4例临床病理分析】。
Pub Date : 2009-11-01 DOI: 10.5732/cjc.009.10011
Zhi-Hui Wang, Huai-Yin Shi, Zhan-Bo Wang

Background and objective: Metastatic alveolar soft tissue sarcoma (ASTS) of the central nervous system is rare and is easy to be misdiagnosed as other primary tumors of central nervous system. This study was to analyze the clinical and pathological features of four patients with ASTS of the central nervous system and to clarify their differential diagnosis as well as prognosis.

Methods: HE slices and clinical data of the four cases were reviewed and immunohistochemical staining was performed. Antibodies included Vimentin, Myosin, Myoglobin, S-100, Actin, Desmin, CgA, Syn, NSE, and CK.

Results: All four patients had a skin nodule of the extremities removed previously. Clinical symptoms included headache and sight blurring. The metastatic lesions were located in the posterior cranial fossa, closely associated with the meninges. The tumor cells had clear or eosinophilic cytoplasm and prominent nucleoli, arranged in alveolar structures, which were surrounded by delicate blood sinuses. The immunohistochemical staining results showed that the positive stainings of Actin, Desmin and S-100 were in 2 cases; the weakly positive stainings of NSE and Vimentin were in 1 case; the positive staining of PAS was in all four cases. The follow-up data showed that one case died during one year after surgery, two cases died during three years. The fourth case had half year after operation and had been alive without tumour.

Conclusion: ASTS of the central nervous system was mostly metastatic and should be differentiated from other CNS tumors such as meningioma, melonocytic tumor, rhabdomyosarcoma and paraganglioma. Metastatic ASTS of the central nervous system had poor prognosis and the five-year survival rate was low.

背景与目的:中枢神经系统转移性肺泡软组织肉瘤(Metastatic alveolar soft tissue sarcoma, ASTS)较为罕见,易误诊为其他中枢神经系统原发肿瘤。本研究旨在分析4例中枢神经系统ast患者的临床及病理特点,明确其鉴别诊断及预后。方法:回顾4例患者的HE切片及临床资料,进行免疫组化染色。抗体包括Vimentin、Myosin、myhemoglobin、S-100、Actin、Desmin、CgA、Syn、NSE和CK。结果:4例患者均有肢端皮肤结节切除。临床症状包括头痛和视力模糊。转移灶位于颅后窝,与脑膜密切相关。肿瘤细胞胞质清晰或嗜酸性,核仁突出,排列在肺泡结构中,被精致的血窦包围。免疫组化染色结果显示2例细胞Actin、Desmin、S-100阳性;NSE、Vimentin弱阳性1例;4例PAS均呈阳性染色。随访资料显示,术后1年内死亡1例,3年内死亡2例。第4例术后半年无肿瘤存活。结论:中枢神经系统ast多为转移性肿瘤,应与脑膜瘤、黑素细胞瘤、横纹肌肉瘤、副神经节瘤等中枢神经系统肿瘤进行鉴别。中枢神经系统转移性ast预后差,5年生存率低。
{"title":"[Metastatic alveolar soft tissue sarcoma of the central nervous system: a clinicopathological analysis of four cases].","authors":"Zhi-Hui Wang,&nbsp;Huai-Yin Shi,&nbsp;Zhan-Bo Wang","doi":"10.5732/cjc.009.10011","DOIUrl":"https://doi.org/10.5732/cjc.009.10011","url":null,"abstract":"<p><strong>Background and objective: </strong>Metastatic alveolar soft tissue sarcoma (ASTS) of the central nervous system is rare and is easy to be misdiagnosed as other primary tumors of central nervous system. This study was to analyze the clinical and pathological features of four patients with ASTS of the central nervous system and to clarify their differential diagnosis as well as prognosis.</p><p><strong>Methods: </strong>HE slices and clinical data of the four cases were reviewed and immunohistochemical staining was performed. Antibodies included Vimentin, Myosin, Myoglobin, S-100, Actin, Desmin, CgA, Syn, NSE, and CK.</p><p><strong>Results: </strong>All four patients had a skin nodule of the extremities removed previously. Clinical symptoms included headache and sight blurring. The metastatic lesions were located in the posterior cranial fossa, closely associated with the meninges. The tumor cells had clear or eosinophilic cytoplasm and prominent nucleoli, arranged in alveolar structures, which were surrounded by delicate blood sinuses. The immunohistochemical staining results showed that the positive stainings of Actin, Desmin and S-100 were in 2 cases; the weakly positive stainings of NSE and Vimentin were in 1 case; the positive staining of PAS was in all four cases. The follow-up data showed that one case died during one year after surgery, two cases died during three years. The fourth case had half year after operation and had been alive without tumour.</p><p><strong>Conclusion: </strong>ASTS of the central nervous system was mostly metastatic and should be differentiated from other CNS tumors such as meningioma, melonocytic tumor, rhabdomyosarcoma and paraganglioma. Metastatic ASTS of the central nervous system had poor prognosis and the five-year survival rate was low.</p>","PeriodicalId":7559,"journal":{"name":"Ai zheng = Aizheng = Chinese journal of cancer","volume":"28 11","pages":"1214-8"},"PeriodicalIF":0.0,"publicationDate":"2009-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28493499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Ai zheng = Aizheng = Chinese journal of cancer
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1